A B S T R A C T Intravenous injection of polyinosinic acid/polycytidylic acid [(poly rI) * (poly rC)] offered significant protection against intranasal challenge of young mice with vesicular stomatitis virus (VSV). Optimal protection was obtained when a single dose was administered 2 hr before virus challenge, but repeated doses were effective when started as late as 3 days after virus challenge. The therapeutic ratio or ratio of maximum tolerated dose to minimum effective dose for a single intravenous injection of (poly rI) *(poly rC) 2 hr before virus inoculation was > 8 mg/kg: 0.004 mg/ kg or > 200. Dose-response curves for interferon production and antiviral protection by (poly rI) -(poly rC) were closely parallel. Equivalent doses of poly rI or poly rC alone did not exert any interferon-inducing capacity or protective effect on intranasal VSV challenge. Several factors, which are known to potentiate or antagonize interferon production, increased or decreased the interferon-inducing capacity and antiviral protection of either (poly rI) * (poly rC) or maleic acid/divinyl ether copolymer (MA/DVE) in parallel. Interferon production and antiviral protection by MA/DVE were enhanced by arginine but abolished by prior treatment with MA/DVE; DEAE-dextran (intraperitoneally), kinetin riboside and isopentenyladenosine, and prior injection of endotoxin reduced both interferon production and antiviral protection by (poly rI) -(poly rC).
INTRODUCTION
The synthetic polyanionic interferon inducers maleic acid/divinyl ether copolymer (MA/DVE) (1) and polyinosinic/polycytidylic acid [(poly rI) * (poly rC)] (2) have been shown effective in protecting young mice from intranasal challenge with vesicular stomatitis virus (VSV) (3). This experimental virus infection, described by Sabin and Olitsky in 1938 (4) , resembles certain natural virus infections in animals and man (e.g. poliomyelitis, rabies, and herpes simplex encephalitis) (5) , in that the virus spreads from a respiratory tract site (olfactory mucosa) through the olfactory nerves to the brain.
As both MA/DVE and (poly rI) (poly rC) offered antiviral protection at a distant site from where they were injected, their antiviral action was assumed to be mediated by interferon production (3) . Protection at a distant site has also been demonstrated for MA/DVE, (poly rI) . (poly rC), and related synthetic polyanions in other acute viral infections such as vaccinia tail lesions in the mouse (6-9,1 3), herpes simplex infection of the rabbit eye (10) , and lethal infections with Columbia SK virus (9, 11) , encephalomyocarditis virus (12) , influenza virus,' and foot and mouth disease in mice (13) . Additional support for the role of interferon in the protection observed in these model infections came from the finding that antiviral protection was 'Claes, P., A. Billiau The Journal of Clinical Investigation Volume 49 1970 maximal when virus challenge was given shortly (2 hr to 1 day) after administration of the polymer, that is, at the time interferon production reached its peak. Polyanionic macromolecules have a wide variety of effects in the whole animal (see Discussion), only one of which is interferon production; hence a temporal relationship between the presence of interferon and antiviral protection is not adequate to prove a causal relationship. More substantial support for the role of interferon in the antiviral activity of synthetic polyanions, came from studies comparing the activity of polycarboxylates (maleic anhydride copolymers, polyacrylic acid, polyacetal carboxylic acids) with different densities of charge. Both interferon production and antiviral protection required a high density of free negative groups and decreased in parallel upon esterification or amidation of the carboxyl groups (maleic anhydride copolymers, polyacrylic acid) or insufficient oxidation of the parent compound (polyacetal carboxylic acids) (6, 14) . 1 The role of interferon in the antiviral protection conferred by MA/DVE and (poly rI) * (poly rC) is further assessed in the present report. First, optimal dose and time were determined for intravenously injected (poly rI) -(poly rC) to protect mice against intranasal VSV challenge. Interferon production and antiviral protection were then compared following injection of graded doses of (poly rI) -(poly rC). Secondly, several factors which specifically antagonize or potentiate interferon production, were examined to see whether they influenced resistance of mice to VSV challenge in parallel. Finally, conclusive evidence for the role of interferon in this protective effect was afforded by simulating serum levels of (poly rI)-(poly rC)-induced interferon with intravenously administered exogenous interferon.
METHODS
Animals. Randomly bred Swiss-Wcbster albino mice were used throughout this study. They were kept in an airconditioned room at 20°C. Young (14 day to 24 day) mice were used for intranasal inoculation with VSV as older mice developed resistance to intranasal inoculation of the virus (3, 4) .
Compounds. Maleic acid/divinyl ether copolymer NCS-46015-C (MA/DVE) ( (20 January 1969) . saline at 1 mg/ml; equal amounts of both polynucleotides were mixed and allowed to react for 1 hr at 250C. Formation of double-stranded (poly rI) -(poly rC) was demonstrated by a marked hypochromic effect at 260 nm and a sharp transition (Tm) at 620C. Small volumes of the stock solution (1 mg/ml) were stored at -20'C. Immediately before use a sample was thawed and diluted in PBS or saline to the appropriate concentration.
Arginine (L-arginine, free base A-grade) and diethylaminoethyl-dextran (DEAE-dextran) were purchased from Calbiochem, Los Angeles, Calif., and Pharmacia, Uppsala, Sweden respectively. Arginine was dissolved in MEM and DEAE-dextran in distilled water or saline just before use.
Salmonella enteritidis endotoxin was obtained from Difco Labs, Detroit, Mich. It was stored at 1 mg/ml or 0.1 mg/ml in saline at 4VC.
Kinetin riboside (6- (6) . The interferon titer corresponded to the reciprocal of the highest dilution of the sample which reduced virus plaque formation by 50%o. Interferon was characterized by its sensitivity to trypsin (1.0 mg/ml, 37°C, 1 hr), thermolability (56°C, 1 hr), nonsedimentability (100,000 g, 2 hr), and species specificity (lack of activity in human skin fibroblasts). 
RESULTS
Dose response effect. Doses of (poly rI). (poly rC) ranging from 0.016 to 8 mg/kg were injected intravenously 2 hr before intranasal challenge with VSV (Fig. 1) . The protection observed was directly proportional to the dose of (poly rI)-(poly rC) employed: per cent survival rose from 10 [control and 0.016 mg/kg of (poly rI)-(poly rC)] to 36 for 0.08 mg/kg of (poly rI). (poly rC), 63 (for 0.4 mg/kg), and to 80 (for 1.6 mg/kg). Raising the dose of (poly rI) * (poly rC) to 8 mg/kg did not further increase the number of surviving mice. From these data a minimum effective dose of 0.04 mg/kg may be calculated and, as (poly rI) * (poly rC) did not show signs of toxicity at the highest dose tested (8 mg/kg), its therapeutic index (with intravenous administration) is greater than 200. The dose of (poly rI) * (poly rC) found to protect mice from a lethal infection with VSV, 2 hr after the intravenous injection of the polymer, was much lower than that reported to confer protection 1 day after intraperitoneal injection (3) .
When a range of (poly rI) (poly rC) dosages were compared for interferon production and antiviral protection, parallel curves were obtained for the doseinterferon production and the dose-antiviral protection effects (Fig. 2) . Both responses as plotted in Fig. 2 were nearly linear from 0.016 mg/kg to 1.6 mg/kg but leveled off at 8 mg/kg, the highest dose tested. No antiviral protection and only minimal interferon production (50 U/4 ml serum) were noted for 0.016 mg/kg of (poly rI). (poly rC). The closely parallel dose-response curves suggest that the protective activity of (poly rI) * (poly rC) in this assay is closely related to interferon production. A direct relationship between the dose of (poly rI) * (poly rC), serum interferon titers, and survival was also established in mice inoculated with foot and mouth disease virus (13) .
Requirement of complementary base-paired complex formation for interferon production and antiviral protection by (poly rI) * (poly rC). The homopolymer pair (poly rI) (poly rC) has been reported to induce interferon production (2, 17) , pyrogenicity (17) , and antiviral protection (13) in animals at doses the homopolymers poly rI and poly rC alone did not (though Baron et al. [18] found some preparations of poly rI and poly rC active in producing interferon in rabbits). Although poly rI and poly rC alone have little, if any, interferon-inducing capacity, they reduced the occurrence of internal adenovirus type 12 tumors in hamsters (19) . Stimulation of immune mechanisms by the homopolymers was suggested as an explanation of the latter effect (19) .
To establish the role of interferon in the resistance induced by (poly rI) (poly rC) against intranasal VSV challenge in mice, poly rI and poly rC were tested for both interferon production and antiviral protection under conditions were (poly rI) * (poly rC) induced high serum interferon titers and conferred significant resistance to virus infection ( Fig. 2) . Table I shows that the single homopolymers poly rI and poly rC did not stimulate either interferon production or protection against intranasal VSV inoculation, whereas (poly rI).
(poly rC) did so. These findings indicate the importance of complementary base-pairing for the protective and interferon-inducing activity of (poly rI). (poly rC) and relate the protection against VSV infection to the interferon produced.
Time response effect. Single or repeated doses of 0.4 mg/kg of (poly rI) (poly rC) were administered intravenously several times either before or after intranasal challenge with VSV ( Fig. 3) . A single injection 2 hr before virus challenge was as effective as daily treatment starting 1 day after infection and continued until the 7th day after infection: with either regimen survival increased by 60%. Treatment begun 3 days after infection and continued daily until the 7th day, increased the number of survivors by 30%. When treatment was delayed until first symptoms of disease (fever, circling, paralysis, convulsions) occurred (5th to 6th day) (3), there was only a minor increase of the mean survival time and percentage of surviving mice. Thus, the protection obtained was closely related to the time treatment was initiated, as was noted previously (3) with intraperitoneal injection of (poly rI) * (poly rC). However, intravenous administration proved more effective than intraperitoneal administration when treatment was started after virus challenge, e.g., 5-10 mg/kg of (poly rI) * (poly rC), injected intraperitoneally at the 3rd and 5th days delayed mortality but did not prevent the eventual death of all mice (3), whereas 0.4 mg/kg of (poly rI) * (poly rC), injected intravenously daily from the 3rd until the 7th day, reduced the final deaths by 30%. The optimal time for a single intravenous administration of (poly rI). (poly rC) appeared to be 2 hr before virus inoculation; the antiviral effect diminished when the time of injection was shifted backwards (16 hr before virus infection) or forwards (32 hr after virus infection) (Fig. 3) . Effect of cations on interferon production and antiviral protection. Several factors, which are known to either antagonize or potentiate interferon production, were studied for their effect on interferon production and antiviral protection by MA/DVE and (poly rI)-(poly rC).
Basic substances such as DEAE-dextran (20-25), neomycin (25, 26) and other polyamines (26) have been shown active in potentiating induction of interferon or cellular resistance to virus infection by (poly rI). (poly rC) in vitro, though not in all cell cultures (26) . DEAE-dextran has also been reported to increase interferon induction by (poly rI) -(poly rC) in the mouse (27) . However, neomycin failed to increase interferon induction by (poly rI) * (poly rC) in the rabbit (26) . So far, there is no evidence that basic substances (DEAE-dextran or neomycin) potentiate the activity of (poly rI) * (poly rC) against experimental viral infections in the whole animal.
Arginine has been observed to increase interferon production in mouse peritoneal macrophages in vitro by MA/DVE, when complexed to MA/DVE at a 3: 1 weight ratio (charge equivalence) (6) . Arginine also increased interferon production by MA/DVE in vivo and increased the antiviral effect of MA/DVE against intranasal VSV challenge in parallel (Table II) . For this effect, both arginine and MA/DVE were injected intraperitoneally. The route of administration may be critical for the enhancing effect of arginine on the antiviral activity of MA/DVE, as arginine failed to increase the protective activity of MA/DVE when both were given intranasally (3) .
Similar experiments were carried out to evaluate the effect of DEAE-dextran on interferon production and antiviral protection by (poly rI) -(poly rC) (Table III) . Intravenous injection of DEAE-dextran had no effect on either induction of interferon or antiviral protection by (poly rI). (poly rC) when they were given simultaneously by the same route. However, intraperitoneal injection of DEAE-dextran markedly reduced the capacity of (poly rI) -(poly rC) to stimulate both interferon production and protection against VSV infection (Table III) . Intraperitoneally injected DEAE-dextran also diminished interferon response to MA/DVE (two- We were interested in whether hyporeactivity to interferon induction was associated with hyporeactivity to antiviral protection. The effects of repeated injectionsof interferon inducers were explored in mice given two doses of MA/DVE 5 days apart, and mice given (poly rI) * (poly rC) 2 days after endotoxin. Both treatment schedules are known to significantly diminish the interferon response to the second stimulus (6, 34, 35) . Pretreatment of mice with MA/DVE not only reduced the interferon-inducing capacity but also abolished the protective activity of a second dose 5 days later (Table IV) .
A single injection of MA/DVE conferred maximal protection when given 1 day before VSV challenge (Table  IV) and was slightly active when given 10 days before virus inoculation (3). The injection of MA/DVE showed very little, if any, activity when given 6 days before virus inoculation (3), (Table IV) . Similarly, prior injection of endotoxin produced a marked decrease in the interferon response to (poly rI) * (poly rC) 2 days later, as well as a decrease in its antiviral effect in the intranasal VSV assay (Table V) . Injection of endotoxin alone, 3 days before virus challenge, did not influence the mortality rate.
The parallelism between hyporeactivity to interferon production and hyporeactivity to antiviral protection, as examined in the two different systems, suggests that both mechanisms are interrelated, the simplest relationship obviously being that interferon production underlies the protective activity of MA/DVE and (poly rI). (poly rC) against intranasal VSV infection in the mouse.
Effect of the nucleoside analogs kinetin riboside and isopentenyladenosine on interferon production and antiviral protection. The plant cytokinines, kinetin riboside and isopentenyladenosine, reverse the stimulatory effects of oligodeoxyribonucleotides and double-stranded RNA's such as (poly rA)-(poly rU) on antibody production (38) (39) (40) and phagocytosis (41); kinetin riboside also antagonizes the effect of endotoxin on host resistance to infection with Pseudomonas aeruginosa (15) . Kinetin riboside and isopentenyladenosine do not inhibit the normal immune response, but only the adjuvant-like effects on antibody production.
As double-stranded RNA has an adjuvant-like effect on normal antibody production (42), as well as initiates interferon production and confers antiviral protection, we examined the effects of kinetin riboside and isopentenyladenosine on interferon production and antiviral protection by (poly rI) * (poly rC). Both nucleoside analogs caused a 4-to 5-fold decrease of the interferon response to (poly rI) * (poly rC) (Fig. 4 a) and decreased the activity of (poly rI) . (poly rC) against intranasal VSV challenge (Fig. 4 b) . Kinetin riboside and isopentenyladenosine did not increase the mortality rate of (poly rI) -(poly rC)-treated mice during the early mortality period (4th to 7th day) but did so during the later period (8th to 14th day). Neither material blocked interferon production or antiviral protection completely.
The parallel effects of kinetin riboside and isopentenyladenosine on both interferon production, antiviral protection (Fig. 4) , phagocytosis (41) , and production of specific antibody (38) (39) (40) support the hypothesis that a common mechanism (release of oligonucleotides ? [43] ) might underlie interferon production, antiviral protection, and the other host resistance mechanisms.
Simulation of the antiviral effect of endogenous interferon uwith exogenous interferon. To directly evaluate the role of interferon in the antiviral protection conferred by (poly rI) -(poly rC), attempts were made to simulate the endogenously produced interferon with exogenous interferon. When the integrated areas under the time response curves were considered, four repeated doses of 400 U of interferon per mouse, injected intravenously 2 hr apart, produced an interferon response in the circulation, which was intermediate between the endogenous interferon levels induced by 0.08 mg/kg and 0.016 mg/kg of (poly rI) -(poly rC) (Fig. 5, a, b , and c: left side). It is of interest that the intravenously administered interferon was cleared rapidly from the circulation but its rate of removal was slower than observed by others (44, 45) . Disappearance was far from complete 2 hr after the injections and about 10% of the original serum titer was detected 2 hr after the 4th interferon injection. Brain interferon titers were measured after injection of interferon and (poly rI) -(poly rC) (0.08 mg/kg) and, though smaller amounts of interferon were found in the brain tissue than in the serum, these levels increased and decreased in parallel (Fig. 5,  a and b: left side) .
The protection against intranasal VSV challenge was closely related to the levels of circulating interferon, no matter where the interferon originated from (exogenous or endogenous): 0.08 mg/kg of (poly rI)-(poly rC) increased the number of surviving mice by 26% (P < 0.05), 0.016 mg/kg of (poly rI) * (poly rC) did not affect survival, but passive interferon treatment increased the survival by 12% (P < 0.30) (Fig. 5, a, b , and c: right side). When the daily death and survival counts (as determined from the day the first animal died to the day to the last animal died in either group) were compared, protection conferred by 0.08 mg/kg of (poly rI) * (poly rC) was significant at the P < 0.001 level and for interferon at the P < 0.005 level, whereas protection by 0.016 mg/kg of (poly rI) * (poly rC) was not significant.
The circulating interferon titers and the antiviral protection obtained with exogenous interferon were both intermediate between the circulating interferon Days ofter i nfecfion FIGURE 4 Effect of kinetin riboside and isopentenyladenosine on interferon production and antiviral protection by (poly rI) * (poly rC). Mortality was produced by 5.100 p.f.u. of VSV in 20 day old mice (10-12 g ) (30 mice per group). Interferon titers were determined in 20-g mice (mean values for three experiments with two mice per group). Both kinetin riboside, isopentenyladenosine, and (poly rI) -(poly rC) were injected intravenously 2 hr before virus challenge or bleeding of animals for interferon determination. Doses: (Poly rI) (poly rC): as indicated for interferon production, 0.4 mg/kg for antiviral protection; kinetin riboside (KR) and isopentenyladenosine (IPA): 50 mg/kg for interferon production, 30 mg/kg for antiviral protection.
production and protective effect of 0.08 and 0.016 mg/ kg of (poly rI) * (poly rC), and appeared to be equivalent to the interferon and resistance-inducing capacity of approximately 0.04 mg/kg of (poly rI) -(poly rC). Thus, under our experimental conditions, (poly rI).
(poly rC) did not offer a better protective effect against intranasal VSV than could be expected from the interferon it produced, indicating that its whole activity was due to interferon production. DISCUSSION The activity of (poly rI) -(poly rC) and other synthetic polyanions has been evaluated against a variety of acute viral infections in experimental models (2, 3, 6-13, 46, 47) ,',' some of which resemble natural virus infections in animals and man (e.g., herpetic keratoconjunctivitis [10] , viral meningo-encephalitis [3] ). Whenever a dose-response relationship for (poly rI) * (poly rC) was established, its minimum effective dose proved far below the maximum tolerated dose: graded doses of (poly rI) * (poly rC) were given prophylactically to mice, infected subcutaneously with Columbia SK virus (11) or intranasally with VSV (Fig. 1) . Intraperitoneal (poly rI) * (poly rC) was effective at 0.2 mg/kg in the first model and intravenous (poly rI) -(poly rC) at 0.04 mg/kg in the second. The maximum tolerated doses of (poly rI) -(poly rC) were 12.5 mg/kg and > 8 mg/kg respectively, indicating a margin of safety (or therapeutic index: ratio of maximum tolerated dose to minimum effective dose) of 60 (first model) and > 200 (second). Intranasal (poly rI) * (poly rC) prevented death in mice infected with mouse pneumonia virus or Columbia SK virus given by the same route, at a dosage level as low as 0.006 mg/kg (9, 46) . As mice did not show a significant behavioral change when given 1 mg/kg of (poly rI) * (poly rC) by the respiratory route a favorable activity to toxicity ratio was also achieved for intranasal administration (46) .
The route of administration of (poly rI) * (poly rC) has been found to be critical as was the time of initiation of treatment and the type of infection in which it was used. Intranasal (poly rI) (poly rC) increased survival ratio of mice infected with intranasal VSV when given shortly before virus, but failed to protect when given after virus challenge (3). In contrast, intraperitoneal (poly rI) -poly rC) (3) and especially intravenous (poly rI) -(poly rC) (Fig. 3 ) conferred significant protection when applied several days after intranasal VSV challenge. However, intraperitoneal (poly rI) * (poly rC), 1 day after virus inoculation, did not decrease the lethal effect of a subcutaneous Columbia SK virus infection (11) . Against intranasally inoculated influenza virus, intranasal (poly rI) * (poly rC) was active, whereas intraperitoneal or intravenous (poly rI) - not (11). In some virus infections, such as herpetic keratoconjunctivitis (10), vaccinia tail lesions (9) , and Columbia SK virus infection, (9), (poly rI) * (poly rC) afforded essentially the same level of protection, regardless of its route of administration.
Interferon is thought to mediate the protective effect of (poly rI) -(poly rC) and other synthetic polyanions in acute viral infections, but there is no direct proof of its role. (Poly rI)-(poly rC) or MA/DVE were also reported to block in mice or hamsters the growth of a variety of malignant tumors, whether or not they are known to contain or to depend on a virus (Friend leukemia [48] [49] [50] , Moloney sarcoma [51, 52] , L-1210 leukemia [53, 54] , adenovirus 12 and SV40 virusinduced tumors [19, 55] , malignant melanoma [56] , RC 19 [Rauscher virus-induced transplantable] tumor [57] , and other transplant tumors [54] ) and to protect mice from lethal infections with bacteria (Listeria monocytogenes [58] , Escherichia coli,' pneumococcus [59] ), fungi (Cryptococcus neoformans [59] ) or protozoa (Plasmodium berghei [60] , Leishmania donovani' 6).-
The possible role of interferon in the anti-tumor, antibacterial, and anti-fungal activity of (poly rI). (poly rC) is even more questionable than its role in the antiviral activity of (poly rI) * (poly rC), as interferon has not yet been shown effective against some tumors, fungal and bacterial infections which are inhibited by (poly rI). (poly rC) (e.g., malignant melanoma [56] , Listeria monocytogenes [58] , Escherichia coli'). Other mechanisms such as stimulation of the reticuloendothelial activity (58, 59, 61) , humoral (42) , and cellular (62) immunity may explain the anti-tumor, -bacterial, and -fungal action of (poly rI) -(poly rC).
Although mechanisms not involving interferon might be quantitatively more important than interferon in the 4Weinstein, M. J., J. A. Waitz, and P. E. Came. 1970. Nature (London). 226 (Fig. 3) ; (b) interferon production and antiviral protection increased almost linearly with increasing doses of (poly rI) * (poly rC), went up at the same dose and leveled off at the same dose (Fig. 2) ; (c) at a dosage level where (poly rI).
(poly rC) was highly active in inducing interferon and protection against intranasal VSV challenge, the single homopolymers poly rI and poly rC failed to stimulate interferon production or confer antiviral protection (Table I) (Tables II, III , IV, and V, Fig. 4) ; (e) administration of exogenous interferon in amounts which closely mimicked the levels of endogenous interferon production by (poly rI) * (poly rC) gave essentially the same antiviral protection as the corresponding dose of (poly rI).
(poly rC) (Fig. 5 ).
In the latter experiments, exogenous interferon proved as effective as endogenous interferon at similar serum levels. In studies performed by Gresser, Fontaine-BroutyBoye, Bourali, and Thomas (12) and Gresser and Bourali (57) exogenous interferon therapy was even more efficacious than treatment with inducers of endogenous interferon (in mice inoculated with encephalomyocarditis virus or RC 19 tumor cells). However, FIGURE 5 Comparison of interferon titers in serum and brain tissue and degree of protection against intranasal VSV challenge, following intravenous injection of either (poly rI) (poly rC) or interferon. Doses: (poly rI) * (poly rC) : single injection of either 0.08 mg/kg (Fig. 5 a) or 0.016 mg/kg (Fig. 5 c) exogenous interferon and interferon inducers were administered in arbitrarily chosen dosages and the treatment regimen used for (poly rI)-(poly rC) (and Newcastle disease virus) was likely to lead to hyporeactivity (10, 28, 36, 37) . Moreover, circulating interferon titers were not determined, so that the efficacy of exogenous versus endogenous interferon treatment could not be compared on the basis of interferon titers obtained in the animal.
